Fahad D. Algahtani

Immunological Features and Hypotheses: Do SARS-CoV and MERS-CoV-Reported Individuals have Immunity against SARS-CoV-2 Infection

Rafat Zrieq, Najoua Haouas, Reem M. Ali, Hamoud F. Alshammari & Fahad D. Algahtani · Journal of Pharmaceutical Research International · 2021

COVID-19 spreads abnormally compared to its counterparts in the same family "beta-coronaviruses". Today, we count more than 130 million affected humans affected by the COVID-19. Therefore, the study of means of prevention and treatment is an urgent need. Interestingly, the novel...

Open access Research Article 10.9734/jpri/2021/v33i26B31480

Diagnostic Strategies of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Operational Recommendations for Health Professionals

Rafat Zrieq, Asma M. Khemakhem, Najoua Haouas, Mohammed G. M. Zeariya, Fares Alshammari & Fahad D. Algahtani · Journal of Pharmaceutical Research International · 2021

Due to the massive impact of the coronavirus disease 2019 (COVID-19) pandemic worldwide, the accurate and early diagnosis and isolation of infected individuals remains the main way of rapidly curtailing the extension of the disease. The increasing incidence of mutations in the vi...

Open access Research Article 10.9734/jpri/2021/v33i38B32116

Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm

Rafat Zreiq, Najoua Haouas, Asma M. Khemakhem, Rawan M. Obeidat, Reem M. Ali, Asma Ayyed AL- Shammary, Bandar Alsaif & Fahad D. Algahtani · Journal of Pharmaceutical Research International · 2020

Coronavirus disease 2019 (COVID-19) is emerging contagious pneumonia due to the new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It initially appeared in Wuhan China in December 2019 then rapidly spread worldwide and became a pandemic. For the time being, there i...

Open access Research Article 10.9734/jpri/2020/v32i2230780